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H istidine-rich glycoprotein (HRG) is a 75 kDa single polypeptide chain protein that was first 
purified from human plasma almost half a century ago 
[1 , 2].  HRG is mainly synthesized in the liver [3] and 
has been shown to be present in the plasma of many 
vertebrates (humans,  mice,  cows,  rats and rabbits) [4] 
as well as in aquatic invertebrates [5].  It is relatively 
abundant,  circulating at a concentration of approxi-
mately 100-150 μg/mL in human blood [6].  Human 
HRG has been analyzed as having 507 amino acids [3] 
in multiple domains: two cystatin-like regions at the 
N-terminus and a histidine-rich region (HRR) flanked 
by two proline-rich regions (PRRs) and a C-terminal 
domain [7].  HRG can simultaneously interacts with 
multiple ligands,  including heparin [2],  heme [8],  Zn2+ 
[9],  plasminogen [10],  fibrinogen [11],  thrombospon-
din (TSP) [12],  tropomysin [13],  vasculostatin [14],  
immunoglobulin G [15],  complement components [16] 
and phospholipids [17] through several independent 
binding sites [18],  thereby regulating numerous bio-
logic processes.  HRG maintains homeostasis of the 
vascular system to provide immediate responses to for-
eign pathogens and vascular damage and has functions 
in modulating coagulation [19],  fibrinolysis [10] and 
angiogenesis [4 , 20] and helping to kill pathogens [21-
23].  In our study,  we also found that HRG interacts 
with many different cell types in blood vessels,  includ-
ing endothelial cells,  erythrocytes,  neutrophils and 
platelets,  to help prevent vascular dysfunction (Fig. 1).  
In this review,  we focus on the roles of HRG in the 
maintenance of vascular homeostasis and regulation of 
angiogenesis.
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Histidine-rich glycoprotein (HRG) is a 75 kDa plasma protein that is synthesized in the liver of many verte-
brates and present in their plasma at relatively high concentrations of 100-150 μg/mL.  HRG is an abundant and 
well-characterized protein having a multidomain structure that enable it to interact with many ligands,  func-
tion as an adaptor molecule,  and participate in numerous physiological and pathological processes.  As a 
plasma protein,  HRG has been reported to regulate vascular biology,  including coagulation,  fibrinolysis and 
angiogenesis,  through its binding with several ligands (heparin,  FXII,  fibrinogen,  thrombospondin,  and plas-
minogen) and interaction with many types of cells (endothelial cells,  erythrocytes,  neutrophils and platelets).  
This review aims to summarize the roles of HRG in maintaining vascular homeostasis and regulating angiogen-
esis in various pathological conditions.
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The Role of HRG on Maintaining Vascular 
Homeostasis
Plasma proteins are essential for a variety of normal 
physiologic processes,  such as coagulation,  fibrinolysis,  
angiogenesis,  tissue remodeling and transporting of 
nutrients,  as well as the detection and clearance of 
unwanted materials such as pathogens,  immune com-
plexes (ICs) and dying/dead cells.  The pathologies of 
many diseases like sepsis include vascular dysfunction 
associated with coagulopathy and dysregulated inflam-
mation/immune responses.  These pathologies are likely 
related to dysregulation of neutrophils,  activation and 
damage of vascular endothelial cells,  enhanced platelet 
aggregation,  immune paralysis,  and procoagulant 
activity.  HRG’s location in plasma as well as its multiple 
ligands within hemostatic pathways have implicated this 
protein as a modulator of hemostasis.
HRG regulates both coagulation and fibrinolysis.
In previous studies,  HRG was found to modulate vari-
ous components of the coagulation cascade through its 
binding with molecules related to coagulation and fibri-
nolysis.  HRG inhibits the procoagulant activity of 
monocytes by blocking the normal interaction between 
heparin and antithrombin III [24-26].  In addition,  it 
has been shown that HRG can act as an antifibrinolytic 
agent due to its high-affinity interaction with plasmino-
gen,  by which it inhibits the interaction of plasminogen 
with fibrin clots,  thus indirectly inhibiting plas-
min-mediated fibrinolysis [27, 28].  This proposed anti-
fibrinolytic effect of HRG would be expected to potenti-
ate clot formation and persistence within the 
vasculature and in tissues.  In contrast,  other studies 
have demonstrated the pro-fibrinolytic role of sur-
face-immobilized HRG [29].  Immobilized HRG binds 
plasminogen with a high affinity,  resulting in an 
approximately 30-fold increase in the conversion of 
plasminogen to plasmin by tPA,  with theoretically a 
concomitant increase in the fibrinolytic potential in the 
microenvironment of fibrin clots.  Collectively,  these 
studies suggest that HRG is an important agent in the 
regulation of coagulation and fibrinolysis.
HRG interacts with several blood cells. The ini-
tial step of the disruption of vascular homeostasis is the 
injury of vascular endothelial cells.  It has been demon-
strated that HRG can protect vascular endothelial cells 
from strong activation and apoptosis induced by lipo-
polysaccharide (LPS) or TNF-α in vitro [30 , 31].  HRG 
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Fig. 1　 HRG helps to maintain the vascular homeostasis.
also can protect against the vascular barrier dysfunction 
of sepsis in mice and can prevent LPS/TNF-a-induced 
cytokine release from endothelial cells in vitro,  thus 
helping to maintain the barrier integrity of the vascular 
endothelium [31].  Moreover,  HRG was also shown to 
inhibit release of the damage-associated molecule-high 
mobility group box-1 (HMGB1) from endothelial cells 
through its binding with the C-type lectin domain fam-
ily 1 member A (CLEC 1A) receptor expressed on 
endothelial cells [32].
HRG plays important roles in neutrophils,  main-
taining their round shape and smooth cell surface and 
suppressing the spontaneous production of reactive 
oxygen species (ROS).  Plasma HRG maintains circulat-
ing neutrophils in the quiescent state,  thereby facilitat-
ing the ease of their passage through capillaries and 
limiting damage to vascular endothelial cells,  which 
may be induced by the ROS released from neutrophils 
[30].  Likewise,  decreased plasma levels of HRG in sep-
sis can result in the adhesion of neutrophils on vascular 
endothelial cells,  with subsequent intravascular 
NETosis and immunothrombosis [30].
Platelets are small cellular fragments derived from 
the budding of megakaryocytes in the bone marrow.  
They play an important role in the regulation of blood 
hemostasis as well as other processes such as immunity,  
tumor metastasis and angiogenesis.  At sites of blood 
vessel injury,  platelets are activated and aggregate to 
prevent hemorrhage.  HRG has been found within 
platelets and has also been reported to be released fol-
lowing platelet activation with thrombin [33].  There are 
studies showing that HRG binds to platelets in a specific 
saturable manner dependent on Zn2+.  Binding is poten-
tiated by thrombin-induced platelet activation [34 , 35].  
HRG−/− mice display a shorter bleeding time than 
HRG+/+ mice,  indicating a role of HRG as a negative 
regulator of platelet function [36].  The underlying 
mechanisms of action are unclear but could involve the 
recruitment of other plasma proteins to the platelet sur-
face.  Candidates that are involved in platelet function 
and binding to HRG are TSPs and vitronectin [37].  
Taken together,  the above-mentioned findings suggest 
a role for HRG both as an anticoagulant,  an antifibri-
nolytic modifier and a regulator of platelet function 
[36].
Since red blood cells (RBCs) play significant func-
tions in blood clotting and related disorders [38],  the 
RBC rheology has been widely studied in different dis-
ease conditions.  Numerous studies have reported on the 
dysregulated adherence of erythrocytes to endothelial 
cells in sickle cell disease (SCD),  malaria and diabetes.  
This adhesion plays a pivotal role in initiating thrombus 
formation after the activation of neutrophils and plate-
lets in immunothrombosis.  HRG also strongly inhibits 
the Zn2+-induced aggregation of erythrocytes and the 
adhesion of erythrocytes to the damaged vascular endo-
thelium: two more of its antithrombotic effects [39].
Functions of HRG in Angiogenesis
In healthy adults,  angiogenesis is rare.  The vascula-
ture is tightly regulated by pro- and anti-angiogenic 
factors,  keeping it quiescent during normal conditions.  
Excessive angiogenesis has been implicated in numer-
ous pathological conditions such as rheumatoid arthri-
tis,  retinopathy and tumor growth,  and the possibility 
of inhibiting the formation and remodeling of blood 
vessels is therefore of great clinical interest [40 , 41].  
This section focuses on the role of HRG in the regula-
tion of both pro- and anti- angiogenic properties.
Pro-angiogenesis activity. There have been 
reports on both the enhancing and inhibitory effects of 
HRG on angiogenesis,  including both specific and more 
general effects on cellular function.  One group reported 
that HRG inhibits the antiangiogenic effect of the 
angiogenesis inhibitor TSP-1 and -2 via the HRG 
N-terminal and C-terminal interfering with the binding 
of TSP to its receptor CD36 (Fig. 2) [42].  HRG can also 
tether plasminogen/plasmin to the surface of endothe-
lial cells,  thereby potentially enhancing cell migration 
and invasion,  which is important during angiogenesis 
among other processes [43].
Anti-angiogenesis activity. Conversely,  some 
researchers have demonstrated HRG’s negative role in 
angiogenesis by various mechanisms [44-46].  HRG can 
bind to heparan sulphate on the extracellular matrix 
(ECM) and mask its heparanase cleavage sites,  thereby 
preventing the release of growth factors from the ECM 
[47].  HRG has also been reported to inhibit endothelial 
cell tube formation and proliferation in vitro [45].  These 
results were later extended with in vivo data,  where HRG 
was shown to inhibit tumor growth and vascularization 
in a subcutaneous fibrosarcoma mouse model,  with the 
antiangiogenic effect mediated by the His/Pro-rich 
domain [45 , 46].
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Concluding Remarks
Vascular dysfunction occurs as a common patho-
logical process in many severe diseases and is accompa-
nied by abnormal coagulation,  fibrinolysis,  inflamma-
tion and activation of various cells in blood.  In this 
review,  we revealed that HRG can protect endothelial 
cells,  neutrophils,  RBC and platelets from overwhelm-
ing activation in pathological processes,  thus regulating 
coagulation and angiogenesis and maintaining homeo-
stasis of the vascular endothelium.  Although HRG has 
been shown to interact with a variety of ligands and to 
regulate numerous biological activities,  much more 
remains to be discovered about this intriguing mole-
cule.
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